Literature DB >> 18607184

The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity.

Sotirios Tsimikas1, Joseph L Witztum.   

Abstract

PURPOSE OF REVIEW: To review emerging data on the relationship between lipoprotein(a) and oxidized phospholipids. RECENT
FINDINGS: We have recently proposed that a unique physiological role of lipoprotein(a) may be to bind and transport proinflammatory oxidized phospholipids and that this interaction may mediate a common biological influence on cardiovascular disease. In a large series of clinical studies performed to date, a very strong correlation was found between plasma levels of lipoprotein(a) and the content of oxidized phospholipids on apolipoprotein B-100 particles (OxPL/apoB), measured by monoclonal antibody E06, which binds the phosphocholine head group of oxidized phospholipids but not native phospholipids. The correlation of OxPL/apoB to lipoprotein(a) is very strong in individuals with small apolipoprotein(a) isoforms (r = approximately 0.95) and modest in individuals with large isoforms (r = approximately 0.60). In-vitro studies have demonstrated that the vast majority of oxidized phospholipids detected by E06 are bound to lipoprotein(a) in human plasma. A similarly strong association with oxidized phospholipids was also documented in transgenic mice overexpressing lipoprotein(a), even in mice not fed atherogenic diets or with overt atherosclerosis.
SUMMARY: A better understanding of the ability of human lipoprotein(a) to bind oxidized phospholipids may allow clinically important insights into the role of oxidized phospholipids and lipoprotein(a) in human atherogenesis and cardiovascular disease and may provide novel diagnostic tools and therapeutic interventions aimed at measuring and treating elevated levels of OxPL/apoB and lipoprotein(a).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607184     DOI: 10.1097/MOL.0b013e328308b622

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  53 in total

1.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.

Authors:  Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss
Journal:  J Lipid Res       Date:  2010-08-16       Impact factor: 5.922

2.  Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts.

Authors:  Celina Edelstein; Ditta Pfaffinger; Ming Yang; John S Hill; Angelo M Scanu
Journal:  Biochim Biophys Acta       Date:  2010-03-24

Review 3.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 4.  Mitochondria as a source and target of lipid peroxidation products in healthy and diseased heart.

Authors:  Ethan J Anderson; Lalage A Katunga; Monte S Willis
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-02       Impact factor: 2.557

Review 5.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

Review 6.  Targeting lipoprotein (a): an evolving therapeutic landscape.

Authors:  Lillian C Man; Erik Kelly; Danielle Duffy
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

7.  Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

Authors:  Fleur M van der Valk; Siroon Bekkering; Jeffrey Kroon; Calvin Yeang; Jan Van den Bossche; Jaap D van Buul; Amir Ravandi; Aart J Nederveen; Hein J Verberne; Corey Scipione; Max Nieuwdorp; Leo A B Joosten; Mihai G Netea; Marlys L Koschinsky; Joseph L Witztum; Sotirios Tsimikas; Niels P Riksen; Erik S G Stroes
Journal:  Circulation       Date:  2016-08-05       Impact factor: 29.690

8.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

Review 9.  Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis.

Authors:  Luis R Lopez; Kazuko Kobayashi; Yukana Matsunami; Eiji Matsuura
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

10.  The role of oxidized phospholipids in atherosclerosis.

Authors:  Judith A Berliner; Norbert Leitinger; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-12-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.